Bronchodilators form the foundation of symptomatic treatment of COPD. Several long-acting
bronchodilators are now available for use in COPD, but publications of large-scale studies of …

Although pharmacological treatment of COPD is codified in different guidelines and strategy
documents, there is abundant evidence of discrepancy between what they suggest and what …

Chronic obstructive pulmonary disease (COPD) is a progressive airway inflammatory
condition that is associated with accelerated decline of lung function and is characterized by …

Background: Treatment guidelines recommend concomitantuse of ipratropium bromide and
inhaled β 2-agonists asseverity of COPD progresses. While the use of these two agents in …

Aim: To examine the burden of respiratory symptoms, quality of life and co-morbid illness in
COPD patients receiving maintenance treatment in a real world setting. Methods: In a single …

Chronic obstructive pulmonary disease (COPD) is a debilitating condition characterised by
progressive, irreversible airflow limitation. The economic and social burden of the disease is …

Randomized trials of triple therapy including an inhaled corticosteroid (ICS) for chronic
obstructive pulmonary disease (COPD) reported remarkable benefits on mortality compared …

Sustained bronchodilation using inhaled medications in moderate to severe chronic
obstructive pulmonary disease (COPD) grades 2 and 3 (Global Initiative for Chronic …

Purpose There is a high prevalence of chronic obstructive pulmonary disease (COPD) in the
United States (US). Although guidelines are available for the treatment of COPD, evidence …

Maintenance bronchodilator therapy with long-acting β-agonists (LABAs) and long-acting
muscarinic antagonists (LAMAs) is the cornerstone treatment for patients with stable chronic …